Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from CellSource Co., Ltd. ( (JP:4880) ).
CellSource Co., Ltd. reported its consolidated financial results for the nine months ending July 31, 2025, showing net sales of ¥2,818 million and a profit attributable to owners of ¥86 million. The company has shifted to consolidated accounting, making year-on-year comparisons unavailable, but it forecasts full-year net sales of ¥3,774 million and a profit of ¥112 million, indicating a positive outlook for the fiscal year.
The most recent analyst rating on (JP:4880) stock is a Hold with a Yen742.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the biotechnology industry and is listed on the Tokyo Stock Exchange. The company focuses on developing and providing innovative cell-based therapies and regenerative medicine solutions.
Average Trading Volume: 55,295
Technical Sentiment Signal: Strong Sell
Current Market Cap: Yen12.13B
See more data about 4880 stock on TipRanks’ Stock Analysis page.